MaxCyte, Inc. Confirmation of Board change (3253Y)
02 1월 2024 - 4:00PM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 3253Y
MaxCyte, Inc.
02 January 2024
MaxCyte Confirms Appointment of Maher Masoud as President, Chief
Executive Officer and Director
ROCKVILLE, MD, January 2, 2024 - MaxCyte, Inc., (NASDAQ: MXCT;
LSE: MXCT), a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell
therapeutics and innovative bioprocessing applications, is pleased
to confirm the appointment of Maher Masoud as President and Chief
Executive Officer of MaxCyte effective as of January 1, 2024. In
addition, Mr. Masoud now serves as a director on MaxCyte's Board of
Directors.
Regulatory
Pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules")
and Schedule Two Paragraph (g) of the
AIM Rules, Mr. Maher Issa Masoud, aged 48 does not currently
have any other directorship or partnership appointments and has not
been a director or a partner of another company within the previous
five years. Mr. Masoud also holds 674,200 options over common stock
of the Company. There is no further information which is required
to be disclosed under Schedule Two, paragraph (g) of the AIM Rules
for Companies in respect of Mr. Masoud.
MaxCyte Contacts:
US IR Adviser +1 415-937-5400
ir@maxcyte.com
Gilmartin Group
David Deuchler, CFA
US Media Relations
Seismic
Valerie Enes
Nominated Adviser and Joint Corporate Broker +1 408-497-8568
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser
ICR Consilium +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation(R) technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology platform, as well as
scientific, technical, and regulatory support, we aim to guide them
on their journey to transform human health. Learn more at
maxcyte.com and follow us on Twitter and LinkedIn .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAUUORRSOUARRR
(END) Dow Jones Newswires
January 02, 2024 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024